$GRAY News
Last published 1y ago
- 1y agoANNXLUMOGRAYAviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of DirectorsBusiness WireAviceda Therapeutics ("Aviceda"), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™)
- 3y agoGRAYGraybug Announces Name and Trading Symbol ChangeGlobeNewswireREDWOOD CITY, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY) (Graybug) today announced that it has changed its name to CalciMedica, Inc. (the Company), which will become effective at 4:02
- 3y agoGRAYGraybug and CalciMedica Enter into Definitive Merger AgreementGlobeNewswire– Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing CalciMedica's pipeline of first-in-class product candidates for life-threatening inflammatory diseases – Combined company
- 4y agoGRAYGraybug Vision Reports Financial Results for the Three and Nine Months Ended September 30, 2022GlobeNewswireREDWOOD CITY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY) ("Graybug" or the "Company"), a clinical-stage biopharmaceutical company focused historically on developing transformative
- 4y agoGRAYGraybug Vision Reports Financial Results for the Three and Six Months Ended June 30, 2022, and Recent Corporate DevelopmentsGlobeNewswireBALTIMORE, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases, today provided an update on recent corporate developments an
- 4y agoGRAYGraybug to Present at the 2022 OIS Retina Innovation SummitGlobeNewswireBALTIMORE, July 06, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced a platform presentation at
- 4y agoGRAYGraybug Announces Review of Strategic AlternativesGlobeNewswireBALTIMORE, June 28, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced that its Board of Directors
- 4y agoGRAYGraybug to Present Clinical Development Plan Update for GB-102 at the 2022 Clinical Trials at the Summit MeetingGlobeNewswireBALTIMORE, May 19, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced that Parisa Zamiri, MD, PhD,
- 4y agoGRAYGraybug to Present Preclinical Data for GB-401 in Primary Open-Angle Glaucoma at the 2022 ARVO Annual MeetingGlobeNewswireBALTIMORE, April 27, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced a poster presentation of p
- 4y agoGRAYGraybug to Present at the 2022 ASCRS Annual MeetingGlobeNewswireBALTIMORE, April 18, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced a platform presentation at
- 4y agoGRAYGraybug Vision Appoints Dirk Sauer to Board of DirectorsGlobeNewswireBALTIMORE, April 13, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced the appointment of Dirk Sa
- 4y agoGRAYGraybug Announces Pipeline Expansion, Current Cash Expected to Deliver Three Clinical Readouts in 2023GlobeNewswirePhase 2 trial with optimized formulation in wet AMD expected to start in fourth quarter of 2022 Phase 1 trial in glaucoma expected to commence in first quarter of 2023 Acquired corneal gene therapy program; Phase 1/2a data expected in fourth quarter o
- 4y agoGRAYGraybug Vision to Host Virtual R&D Day on March 30, 2022GlobeNewswireBALTIMORE, March 21, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced that it will host a virtua
- 4y agoGRAYGraybug Vision Reports Full Year 2021 Financial Results and Recent Corporate DevelopmentsGlobeNewswireBALTIMORE, March 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today provided an update on recent corpora
- 4y agoGRAYGraybug to Participate in Three Upcoming Medical and Investor ConferencesGlobeNewswireBALTIMORE, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced its
- 4y agoGRAYGraybug Vision Makes Key Hires to Further Build Momentum Behind its PipelineGlobeNewswireBALTIMORE, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced the
- 4y agoGRAYGraybug Vision to Participate in the Piper Sandler 33rd Annual Virtual Healthcare ConferenceGlobeNewswireBALTIMORE, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced that
- 5y agoGRAYGraybug Vision Announces Financial Results for the Three and Nine Months Ended September 30, 2021, and Recent Corporate DevelopmentsGlobeNewswireBALTIMORE, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today provided an up
- 5y agoGRAYGraybug Vision to Participate in the American Academy of Ophthalmology 2021 Annual MeetingGlobeNewswireBALTIMORE, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced two
- 5y agoGRAYGraybug Vision to Participate in the Annual Ophthalmology Innovation Summit (OIS) Retina@ASRS ConferenceGlobeNewswireBALTIMORE, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced tha
- 5y agoGRAYGraybug Vision Reports Analysis of Data from the Six-Month Extension Study of the ALTISSIMO Phase 2b Trial in Wet AMDGlobeNewswire55% of GB-102 1mg patients in Extension Study experienced duration of 12+ months, while maintaining their visual acuity and central retinal thickness 73% reduction of injection burden for patients participating in Extension Study GB-102 1mg cont
- 5y agoGRAYGraybug Vision to Participate in the Cantor Virtual Global Healthcare ConferenceGlobeNewswireBALTIMORE, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced tha
- 5y agoGRAYGraybug Vision Announces Financial Results for the Three and Six Months Ended June 30, 2021, and Recent Corporate DevelopmentsGlobeNewswireREDWOOD CITY, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today pro
- 5y agoGRAYGraybug Vision to Participate in the 2021 Wedbush PacGrow Healthcare Virtual ConferenceGlobeNewswireREDWOOD CITY, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today ann
- 5y agoCRNXDMACGRAYDiaMedica Therapeutics Elects Two Industry Veterans to Its Board of DirectorsBusiness WireAmy Burroughs and Dr. Charles Semba Bring Extensive and Complementary Experience in Building Specialty Therapeutics Companies DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments
- 5y agoAPTXGRAYIBIOJAGX+1Thinking about buying stock in Vaxart, Graybug Vision, Jaguar Health, iBio, or Aptinyx?PR NewswireNEW YORK, June 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VXRT, GRAY, JAGX, IBIO, and APTX.
- 5y agoGRAYGraybug Vision Announces First Quarter 2021 Financial Results and Recent Corporate DevelopmentsGlobeNewswireREDWOOD CITY, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today prov
- 5y agoGRAYGraybug Vision Reports Full-Data Analysis from 12-Month Treatment Phase of ALTISSIMO Phase 2b Trial in Wet AMDGlobeNewswireGB-102 1mg has shown competitive durability and anatomical control versus aflibercept Trend in mean BCVA of GB-102 1mg compared to aflibercept driven primarily by a subgroup of patients Developing enhanced formulations and seeking partner funding for
- 5y agoGRAYGraybug Vision to Report Full-Data Analysis of the 12-month Treatment Phase of its Phase 2b ALTISSIMO TrialGlobeNewswireREDWOOD CITY, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today anno
- 5y agoGRAYGraybug Vision Reports Preliminary Topline Results from Phase 2b ALTISSIMO TrialGlobeNewswireMedian time to first supportive therapy was 5 months for GB-102 1mg48% of patients in the GB-102 1 mg arm were rescue-free for at least 6 monthsControl of retinal thickness was consistent across all...
- 5y agoGRAYGraybug Vision Announces Full Year 2020 Financial Results and Recent Corporate DevelopmentsGlobeNewswireREDWOOD CITY, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the...
- 5y agoGRAYGraybug Vision to Participate in SVB Leerink Global Healthcare ConferenceGlobeNewswireREDWOOD CITY, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat...
- 5y agoGRAYGraybug Vision Appoints Bettina Maunz as Chief People Officer, Expanding the Company’s Executive TeamGlobeNewswireREDWOOD CITY, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat...
- 5y agoGRAYGraybug Vision Completes Treatment Phase of ALTISSIMO Trial in Wet AMD with 12-Month Topline Data Expected in Second Quarter 2021GlobeNewswireREDWOOD CITY, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat...
- 5y agoGRAYEluminex Biosciences, an Ophthalmology-Focused Biotechnology Company, Announces Closing of $50 Million Series A FinancingPR NewswireEluminex Biosciences Limited (Eluminex), an ophthalmic biotechnology company committed to the discovery and development of first-in-class and/or...
- 5y agoGRAYGraybug Vision to Participate in the 32nd Annual Piper Sandler Healthcare ConferenceGlobeNewswireREDWOOD CITY, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the...
- 6y agoGRAYGraybug Vision Announces Financial Results for the Three and Nine Months Ended September 30, 2020 and Recent Corporate DevelopmentsGlobeNewswireREDWOOD CITY, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the...
- 6y agoGRAYAffaMed Therapeutics Announces Merger with EverInsight Therapeutics and Appoints Dayao Zhao, M.D., Ph.D. as CEOGlobeNewswireSHANGHAI, China, Oct. 14, 2020 (GLOBE NEWSWIRE) -- AffaMed Therapeutics (“AffaMed”), a biopharmaceutical company focused on developing and commercializing transformative therapeutics to address...
- 6y agoDVAXGRAYHARPReCode Therapeutics Appoints Julie Eastland as Chief Operating Officer and Chief Financial OfficerBusiness WireMENLO PARK, Calif. & DALLAS--(BUSINESS WIRE)--ReCode Therapeutics™ (ReCode) (the Company), a private biopharmaceutical company pioneering disease-modifying medicines for the treatment of life-limiting respiratory diseases, today announced the appointment of Julie Eastland as chief operating officer (COO) and chief financial officer (CFO). Eastland will oversee the company’s financial and business ...
- 6y agoGRAYGraybug Appoints Three New Members to its Board of DirectorsGlobeNewswireREDWOOD CITY, Calif., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat...
- 6y agoGRAYGraybug Vision Announces Pricing of Upsized Initial Public OfferingGlobeNewswireREDWOOD CITY, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat...